DK2979700T3 - Antitumormiddel, der indbefatter en lav irinotecanhydrochloridhydrat - Google Patents
Antitumormiddel, der indbefatter en lav irinotecanhydrochloridhydrat Download PDFInfo
- Publication number
- DK2979700T3 DK2979700T3 DK14773638.3T DK14773638T DK2979700T3 DK 2979700 T3 DK2979700 T3 DK 2979700T3 DK 14773638 T DK14773638 T DK 14773638T DK 2979700 T3 DK2979700 T3 DK 2979700T3
- Authority
- DK
- Denmark
- Prior art keywords
- day
- dose
- combination drug
- administered
- cancer
- Prior art date
Links
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 title claims description 118
- 229960000779 irinotecan hydrochloride Drugs 0.000 title claims description 51
- 229940000425 combination drug Drugs 0.000 claims description 100
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 72
- 229960003962 trifluridine Drugs 0.000 claims description 72
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- KGHYQYACJRXCAT-UHFFFAOYSA-N tipiracil hydrochloride Chemical compound Cl.N1C(=O)NC(=O)C(Cl)=C1CN1C(=N)CCC1 KGHYQYACJRXCAT-UHFFFAOYSA-N 0.000 claims description 49
- 229960001740 tipiracil hydrochloride Drugs 0.000 claims description 47
- 230000000259 anti-tumor effect Effects 0.000 claims description 42
- 239000007787 solid Substances 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 36
- 239000002246 antineoplastic agent Substances 0.000 claims description 30
- 206010009944 Colon cancer Diseases 0.000 claims description 26
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 22
- 238000009097 single-agent therapy Methods 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 14
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 14
- 206010017758 gastric cancer Diseases 0.000 claims description 14
- 201000005202 lung cancer Diseases 0.000 claims description 14
- 208000020816 lung neoplasm Diseases 0.000 claims description 14
- 201000011549 stomach cancer Diseases 0.000 claims description 14
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 11
- 206010008342 Cervix carcinoma Diseases 0.000 description 10
- 206010033128 Ovarian cancer Diseases 0.000 description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 10
- 201000010881 cervical cancer Diseases 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000020138 yakult Nutrition 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- -1 etc.) Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000000488 breast squamous cell carcinoma Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000000932 closed testing procedure Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012058 intersection union test Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000013274 squamous cell breast carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000337 synergistic cytotoxicity Toxicity 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
- ANTITUMORMIDDEL, DER INDBEFATTER EN LAV IRINOTECANHYDROCHLORIDHYDRAT1. Antitumormiddel til anvendelse i behandling af solide cancere, hvor et kombinationslægemiddel, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5 administreres, ved anvendelse af en reduceret mængde trifluridin, ved en dosis i intervallet fra 35 til 70 mg/m2/dag, og irinotecanhydrochloridhydrat administreres ved en dosis i intervallet fra 45 til 144 mg/m2/dag.
- 2. Antitumormiddel til anvendelse ifølge krav 1, hvor kombinationslægemidlet, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5, administreres, ved anvendelse af en reduceret mængde trifluridin, ved en dosis i intervallet fra 70 mg/m2/dag ved anvendelse af en reduceret mængde trifluridin, hvor fortrinsvis irinotecanhydrochloridhydrat administreres ved en dosis i intervallet fra 75 til 120 mg/m2/dag.
- 3. Antitumormiddel til anvendelse ifølge krav 1 eller 2, hvor den solide cancer er colorektalcancer, lungecancer, brystcancer, pankreascancer eller gastrisk cancer.
- 4. Antitumormiddel til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor én cyklus af en administrationsplan, hvori, i en periode på 28 dage, et kombinationslægemiddel, der indeholder α,α,α-trifluorothymidin og 5-chlor-6-(2-iminopyrrolidin-l-yl)methyl-2,4(lH,3H)-pyrimidindionehydrochlorid i et molforhold på 1:0,5 administreres på dag 1 til 5 og på dag 8 til 12, og CPT-11 administreres på dag 1 og 15, gentages én eller to eller flere gange.
- 5. Middel til anvendelse i forstærkning af en antitumoreffekt, hvilket middel omfatter et kombinationslægemiddel, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5, til forbedring af irinotecanhydrochloridhydrats antitumoreffekt hos en patient med en solid cancer, hvor kombinationslægemidlet, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5, administreres, ved anvendelse af en reduceret mængde trifluridin, ved en dosis i intervallet fra 35 til 70 mg/m2/dag, og irinotecanhydrochloridhydrat administreres ved en dosis i intervallet fra 45 til 144 mg/m2/dag.
- 6. Antitumormiddel til anvendelse ifølge krav 1, der omfatter kombinationslægemidlet til behandling af en patient med en solid cancer, som har modtaget irinotecanhydrochloridhydrat.
- 7. Kombinationslægemiddel, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5 til anvendelse ved behandling af en solid cancer, hvor kombinationslægemidlet, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5, administreres, ved anvendelse af en reduceret mængde trifluridin ved en dosis i intervallet fra 35 til 70 mg/m2/dag, og irinotecanhydrochloridhydrat administreres ved en dosis i intervallet fra 45 til 144 mg/m2/dag.
- 8. Kombinationslægemiddel til anvendelse ifølge krav 7, hvor kombinationslægemidlet, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5, administreres, ved anvendelse af en reduceret mængde trifluridin, ved en dosis på 70 mg/m2/dag.
- 9. Kombinationslægemiddel til anvendelse ifølge krav 7 eller 8, hvor irinotecanhydrochloridhydrat administreres ved en dosis i intervallet fra 75 til 120 mg/m2/dag.
- 10. Kombinationslægemiddel til anvendelse ifølge et hvilket som helst af kravene 7 til 9, hvor den solide cancer er colorektalcancer, lungecancer, brystcancer, pankreascancer eller gastrisk cancer.
- 11. Kombinationslægemiddel til anvendelse ifølge et hvilket som helst af kravene 7 til 10, hvor én cyklus af en administrationsplan, hvori, i en periode på 28 dage, kombinationslægemidlet, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5, administreres på dag 1 til 5 og på dag 8 til 12, og CPT-11 administreres på dag 1 og 15, gentages én eller to eller flere gange.
- 12. Kombinationslægemiddel, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5 til anvendelse i forbedring af irinotecanhydrochloridhydrats antitumoreffekt i en behandling af en patient med en solid cancer, hvor kombinationslægemidlet, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5 administreres, ved anvendelse af en reduceret mængde trifluridin, ved en dosis i intervallet fra 35 til 70 mg/m2/dag, og irinotecanhydrochloridhydrat administreres ved en dosis i intervallet fra 45 til 144 mg/m2/dag.
- 13. Kombinationslægemiddel til anvendelse ifølge krav 7 til behandling af en patient med en solid cancer, der har modtaget irinotecanhydrochloridhydrat.
- 14. Antitumormiddel til anvendelse i behandling af solide cancere, hvor et kombinationslægemiddel, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5, administreres i kombination med irinotecanhydrochloridhydrat, hvor dosen af kombinationslægemidlet, der indeholder trifluridin og tipiracilhydrochlorid i et molforhold på 1:0,5 er 50 % til 100 % af den anbefalede dosis i monoterapien, og dosen af irinotecanhydrochloridhydrat er 25 % til 80 %, fortrinsvis 50 % til 70 %, af den anbefalede dosis i monoterapien.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013066074 | 2013-03-27 | ||
| PCT/JP2014/058733 WO2014157444A1 (ja) | 2013-03-27 | 2014-03-27 | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2979700T3 true DK2979700T3 (da) | 2019-01-21 |
Family
ID=51624406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14773638.3T DK2979700T3 (da) | 2013-03-27 | 2014-03-27 | Antitumormiddel, der indbefatter en lav irinotecanhydrochloridhydrat |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9616081B2 (da) |
| EP (1) | EP2979700B1 (da) |
| JP (1) | JP6002835B2 (da) |
| KR (1) | KR101848131B1 (da) |
| AU (1) | AU2014245147B2 (da) |
| CY (1) | CY1120990T1 (da) |
| DK (1) | DK2979700T3 (da) |
| ES (1) | ES2702911T3 (da) |
| HR (1) | HRP20182145T1 (da) |
| HU (1) | HUE041687T2 (da) |
| LT (1) | LT2979700T (da) |
| PL (1) | PL2979700T3 (da) |
| PT (1) | PT2979700T (da) |
| RS (1) | RS58067B1 (da) |
| RU (1) | RU2668125C2 (da) |
| SI (1) | SI2979700T1 (da) |
| SM (1) | SMT201800677T1 (da) |
| TR (1) | TR201819576T4 (da) |
| TW (1) | TWI641374B (da) |
| UA (1) | UA117581C2 (da) |
| WO (1) | WO2014157444A1 (da) |
| ZA (1) | ZA201507444B (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| KR101847252B1 (ko) | 2013-03-27 | 2018-04-09 | 다이호야쿠힌고교 가부시키가이샤 | 이리노테칸염산염 수화물을 함유하는 항종양제 |
| HRP20230523T1 (hr) * | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| AU2021258464A1 (en) * | 2020-04-24 | 2023-01-05 | Sanofi | Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| KR100424934B1 (ko) | 1995-03-29 | 2004-07-27 | 다이호야쿠힌고교 가부시키가이샤 | 우라실유도체및이를함유하는항종양효과증강제및항종양제 |
| MX2007003314A (es) * | 2004-09-22 | 2007-08-06 | Pfizer | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas. |
| CA2594482C (en) * | 2005-01-19 | 2013-10-01 | Zeria Pharmaceutical Co., Ltd. | Antitumor agent |
| US7799783B2 (en) | 2005-01-26 | 2010-09-21 | Taiho Pharmaceutical Co., Ltd. | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP5576591B2 (ja) * | 2005-01-26 | 2014-08-20 | 大鵬薬品工業株式会社 | α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
| GB0506708D0 (en) * | 2005-04-01 | 2005-05-11 | Queen Mary & Westfield College | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
| GR20060100144A (el) | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| JP5339373B2 (ja) * | 2006-07-14 | 2013-11-13 | ディーエスエム アイピー アセッツ ビー．ブイ． | 組成物および炎症障害の治療、共治療または予防のためのその使用 |
| JP2011157298A (ja) * | 2010-02-01 | 2011-08-18 | Aska Pharmaceutical Co Ltd | 胃潰瘍治療剤 |
-
2014
- 2014-03-27 JP JP2015508649A patent/JP6002835B2/ja active Active
- 2014-03-27 HU HUE14773638A patent/HUE041687T2/hu unknown
- 2014-03-27 ES ES14773638T patent/ES2702911T3/es active Active
- 2014-03-27 PT PT14773638T patent/PT2979700T/pt unknown
- 2014-03-27 DK DK14773638.3T patent/DK2979700T3/da active
- 2014-03-27 EP EP14773638.3A patent/EP2979700B1/en active Active
- 2014-03-27 SI SI201430982T patent/SI2979700T1/sl unknown
- 2014-03-27 PL PL14773638T patent/PL2979700T3/pl unknown
- 2014-03-27 RS RS20181521A patent/RS58067B1/sr unknown
- 2014-03-27 TW TW103111512A patent/TWI641374B/zh active
- 2014-03-27 HR HRP20182145TT patent/HRP20182145T1/hr unknown
- 2014-03-27 WO PCT/JP2014/058733 patent/WO2014157444A1/ja not_active Ceased
- 2014-03-27 RU RU2015145997A patent/RU2668125C2/ru active
- 2014-03-27 AU AU2014245147A patent/AU2014245147B2/en active Active
- 2014-03-27 LT LTEP14773638.3T patent/LT2979700T/lt unknown
- 2014-03-27 UA UAA201510465A patent/UA117581C2/uk unknown
- 2014-03-27 US US14/779,759 patent/US9616081B2/en active Active
- 2014-03-27 SM SM20180677T patent/SMT201800677T1/it unknown
- 2014-03-27 TR TR2018/19576T patent/TR201819576T4/tr unknown
- 2014-03-27 KR KR1020157026552A patent/KR101848131B1/ko active Active
-
2015
- 2015-10-07 ZA ZA2015/07444A patent/ZA201507444B/en unknown
-
2018
- 2018-12-18 CY CY181101357T patent/CY1120990T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6002835B2 (ja) | 2016-10-05 |
| AU2014245147A1 (en) | 2015-10-15 |
| RU2015145997A (ru) | 2017-05-04 |
| RU2668125C2 (ru) | 2018-09-26 |
| LT2979700T (lt) | 2018-12-27 |
| SI2979700T1 (sl) | 2019-01-31 |
| PL2979700T3 (pl) | 2019-03-29 |
| CY1120990T1 (el) | 2019-12-11 |
| US9616081B2 (en) | 2017-04-11 |
| HUE041687T2 (hu) | 2019-05-28 |
| SMT201800677T1 (it) | 2019-01-11 |
| TR201819576T4 (tr) | 2019-01-21 |
| HRP20182145T1 (hr) | 2019-03-08 |
| ES2702911T3 (es) | 2019-03-06 |
| EP2979700A4 (en) | 2016-11-23 |
| RS58067B1 (sr) | 2019-02-28 |
| TW201513864A (zh) | 2015-04-16 |
| EP2979700A1 (en) | 2016-02-03 |
| ZA201507444B (en) | 2017-01-25 |
| US20160082031A1 (en) | 2016-03-24 |
| JPWO2014157444A1 (ja) | 2017-02-16 |
| WO2014157444A1 (ja) | 2014-10-02 |
| UA117581C2 (uk) | 2018-08-27 |
| AU2014245147B2 (en) | 2017-08-31 |
| PT2979700T (pt) | 2018-12-27 |
| KR20150136074A (ko) | 2015-12-04 |
| TWI641374B (zh) | 2018-11-21 |
| KR101848131B1 (ko) | 2018-04-11 |
| EP2979700B1 (en) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2979700T3 (da) | Antitumormiddel, der indbefatter en lav irinotecanhydrochloridhydrat | |
| DK2799070T3 (da) | Virkningsforstærker til antitumormidler | |
| JP6557744B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| WO2015061832A1 (en) | Pharmaceutical combinations for the treatment of cancer | |
| EP2979701B1 (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| JP6458007B2 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP6488280B2 (ja) | タキサン系化合物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| NZ740252B2 (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| NZ740252A (en) | Antitumor agent including low-dose irinotecan hydrochloride hydrate | |
| JP2015199678A (ja) | ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2015199677A (ja) | ノギテカン塩酸塩を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |